FCPA/Anti-Corruption Compliance in Life Sciences and Pharmaceutical Industry: A 2017 Update
True to its promise, the U.S. Securities and Exchange Commission (SEC) is returning focus on the pharma industry after a break for a number of years. Recently, following several other SEC resolutions in the life sciences sector, the SEC has announced its settlement with AstraZeneca PLC. The company’s Chinese and Russian subsidiaries were alleged to have violated the Foreign Corrupt Practices Act’s (FCPA) internal controls and recordkeeping requirements, resulting in AstraZeneca’s payment of $4,325,000 in profit disgorgement, $822,000 in prejudgment interest and $375,000 for civil penalty.
With this renewed focus on the industry and the increased international cooperation, pharmaceutical companies should ensure that a strong anti-corruption compliance program is in place.
In this two-hour LIVE Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant FCPA updates and developments in 2016 for the pharmaceutical industry and will provide a comprehensive outlook for the year ahead. Speakers will also provide expert insights on the best practices for FCPA compliance.
Key topics include:
- FCPA/Anti-Corruption in Pharmaceutical Industry: Current Trends
- Notable Cases
- Common Anti-Corruption Risks
- Best Compliance Practices
- Regulatory Forecast
- Survey of Whistleblower Complaints from the Front Lines
Glenn Pomerantz, CPA, CFE, Partner, Global Forensics Practice
- Overview of program coverage and interview-type format
Mary Bennett, Vice President, Advisory Services
- Results from Navex's annual benchmark survey, with a focus on the pharmaceutical industry.
Jeffrey Antoon, Director of Internal Audit
Johnson & Johnson
Gary Fair, VP of Corp Internal Audit
Johnson & Johnson
In-house view from Pharma/Life Science industry, covering:
- compliance and internal audit and how they work together;
- need for effectiveness in prevention and detection;
- effective ways of training a global workforce;
- creating an ethical business environment across multiple cultures;
- effective internal audit techniques for detecting corruption.
SEGMENT 4: Jane H. Yoon, Of Counsel
- Enforcement actions in Life Sciences: trends, what companies are doing right and wrong, where global enforcement is headed, the resurgence of FCPA monitorships, the FCPA Pilot Program and the pros and cons of cooperation.
Who Should Attend:
- Legal Counsel
- Health Care Providers
- Risk and Compliance Managers
- Medical Device Regulatory Officers
- Pharmaceutical Regulatory Officers
- Senior Management
- General Counsel
- Life Sciences and Healthcare Industries
Glenn Pomerantz is a Partner in BDO Consulting with over 30 years of forensic accounting, auditing and consulting experience and leads BDO’s Global Forensic Practice. Mr. Pomerantz is a Certified Public Accountant and Certified Fraud Examiner specializing in fraud investigations, compliance and due diligence. His experience includes fraud investigations pertaining to allegations of corruption, theft and embezzlement as well as financial reporting fraud. Mr. Pomerantz has particular expertise in FCPA investigations, asset tracing, and other cross border fraud and corruption matters having led such matters across several continents.
Glenn Pomerantz is a Partner in BDO Consulting with over 30 years of forensic accounting, auditing and consulting experience and …
Mary Bennett, R.Ph. is vice president of Advisory Services at NAVEX Global and is a pharmacist by training. At NAVEX, Mary is responsible for developing, implementing and updating various elements of corporate compliance and ethics programs. She has a proven track record in the E&C space through her work in risk, program and culture assessment, training development and delivery for all employee levels. She previously served as vice president in the Compliance and Integrity office at Caremark, where she implemented the requirements of one of the first government agreements in healthcare. Mary works across all industries for the advisory services team creating award-winning training programs, conducting large and small program assessments, developing compliance communications and helping clients develop best practice programs from the ground up.
Mary Bennett, R.Ph. is vice president of Advisory Services at NAVEX Global and is a pharmacist by training. At NAVEX, …
Jeff Antoon, Director Internal Audit, joined Johnson & Johnson in June 1987 as an Auditor.
As Director of Corporate Internal Audit’s Audit Services Group, Jeff is responsible for worldwide audits in the areas of Foreign Corrupt Practices Act, and Sensitive Issue (fraud) reviews.
Jeff has delivered presentations at various Johnson & Johnson and industry conferences. His external presentations include the Institute of Internal Auditors, Association of Corporate Counsels, the Center for Business Intelligence, the American Conference Institute, c5, exl pharma, American Leaders, Q1 Productions, Marcus Evans, and The Economist.
Prior to joining Johnson & Johnson, Jeff worked for two years each at PricewaterhouseCoopers and Engelhard Corporation. He has a Bachelors degree in Accounting from Villanova University, and a Masters in Business Administration from the University of Maryland. Jeff is a Certified Public Accountant.
Jeff Antoon, Director Internal Audit, joined Johnson & Johnson in June 1987 as an Auditor. As Director of Corporate Internal …
Gary Fair is a Senior Financial Leader for one of the largest corporations in the world. He has a broad base of senior leadership experience in all of Johnson & Johnson’s businesses: pharmaceutical, medical devices and diagnostics, consumer, and corporate governance. A proven executive with strategic vision and tactical execution, Gary has changed culture and business models to drive growth, market expansion, and performance across the J&J family of companies. He has been recognized for his exceptional organizational skills in attracting, developing and promoting diverse individuals throughout the enterprise.
He is currently the Chief Audit Executive and Vice President of Johnson & Johnson’s (J&J) Corporate Internal Audit organization, reporting directly to the CFO and external Board of Directors. In this capacity, Gary is responsible for the leadership of the global internal audit function, including the annual Sarbanes-Oxley Section 404 and Conduct on Business Conduct certifications. He is a member of J&’s Compliance Committee where he is charged with providing leadership to financial and non-financial compliance (Healthcare Compliance, Foreign Corrupt Practices Act Compliance, For-Cause Investigations, Due Diligence of Targeted Acquisitions, Anti-Counterfeiting, Triage Committee for investigative activities) across the enterprise. He is a sought after speaker on the topics of Leadership, Diversity, and Foreign Corrupt Practices.
Prior to his CAE role, Gary was the CFO for the Consumer Pharmaceuticals and Nutritionals Group responsible for the worldwide activities of the McNeil OTC, McNeil Nutritionals, McNeil Pediatric Pharmaceuticals, Ortho Women’s Health & Urology and Johnson & Johnson / Merck Joint Venture franchises. During his 36 year tenure with Johnson & Johnson he was also the inaugural CFO of the Global Pharmaceutical Supply Group which consolidated worldwide supply chain responsibilities for J&J Pharmaceuticals, and the CFO of Vistakon Americas division of J&J Vision Care.
Gary is a past recipient of the J&J Affirmative Action & Equal Opportunity award and currently serves as the Executive Sponsor at J&J for the: J&J Finance Latino Leadership Council (FLLC), ALPFA (Association of Latin Professionals for America), and the J&J Corporate Chapter of HOLA (Hispanic Organization for Leadership and Achievement). In addition to his career with J&J, Gary has been an active community volunteer, having served as a Board of Director and Executive Committee member of non-profit organizations such as, Janssen Ortho Patient Assistance Foundation, Hospice of Northeast Florida, Hospital Home Healthcare and Hospice of New Mexico, The Rehabilitation Center of Albuquerque, and the Audit Committee of the Board of Trustees at Bryn Mawr College.
Gary is a graduate of the University of Notre Dame with a degree in Finance, a native of New York City, and currently resides north of Philadelphia.
Gary Fair is a Senior Financial Leader for one of the largest corporations in the world. He has a broad …
Jane H. Yoon is Of Counsel in the Litigation practice of Paul Hastings and is based in the firm’s New York office.
Prior to joining Paul Hastings, Ms. Yoon was an Assistant United States Attorney in the Health Care and Government Fraud Unit in the U.S. Attorney’s Office for the District of New Jersey. Ms. Yoon led numerous investigations into health care fraud offenses, including investigations and prosecutions of fraud against the government and private health insurance plans, illegal kickback schemes, violations of the Federal Food, Drug & Cosmetic Act, False Claims Act cases, and the improper diversion of prescription drugs. She also investigated complex tax fraud offenses and cases involving fraud against various government agencies.
Jane H. Yoon is Of Counsel in the Litigation practice of Paul Hastings and is based in the firm’s New …
Print and review course materials
Method of Presentation:
Experience in corporate or life sciences law
NASBA Field of Study:
Specialized Knowledge - Technical
NY Category of CLE Credit:
Areas of Professional Practice
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
Get Your 1-Year All Access Pass For Only $199
About BDO Consulting
About BDO’s Global Forensics Practice
The Global Forensics practice at BDO provides insight and forensic resources for high-stakes matters involving fraud and corruption, accounting irregularities, and compliance issues. Around the world, and across all major industries, we are recognized for the depth of our understanding, the breadth of our resources, and the credibility of our analyses. Learn more at bdo.global
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Our over 125,000 employees in 60 countries are united in a common mission: To help people everywhere live longer, healthier, happier lives.
Johnson & Johnson, through its family of companies, is engaged in the research and development, manufacture and sale of a broad range of products in the health care field in virtually all countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Johnson & Johnson operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care, oral care skin care, and wound care products. This segment also provides over-the-counter medicines, including acetaminophen products, cold, flu, and allergy products, and ibuprofen products. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics.
About Paul Hastings
Paul Hastings provides innovative compliance and legal solutions to many of the world's top pharmaceutical and life sciences companies, large and small, in markets across Asia, Europe, Latin America, and the United States. We offer a complete portfolio of services to support our clients' complex, often mission-critical needs--from structuring transactions, to protecting critical intellectual property, to resolving complicated U.S. healthcare and global anti-corruption enforcement matters, to providing the savvy compliance and legal counsel that keeps business moving forward.
Paul Hastings has grown steadily and strategically along with our clients across global markets in the critical pharmaceutical and life sciences sector. We have a significant and strategic presence across Europe, and were one of the first U.S. law firms to establish a presence in Asia, where we continue to be a leader in the region, and have significantly expanded our support for clients in Brazil, out of our new São Paulo office, and other emerging markets of Latin America.